We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Patent Office Nixes Inter Partes Review for Ampyra
Patent Office Nixes Inter Partes Review for Ampyra
A drug pricing watchdog was rebuffed on Aug. 25 in its attempt to get the U.S. Patent and Trademark Office to review two patents on Acorda Therapeutics’ blockbuster multiple sclerosis drug Ampyra — the first of 18 petitions the Coalition for Affordable Drugs has filed with the agency since February.